Clinical trials contribute significantly to a country's health and budget, benefiting patients, investigators, and the entire system.
The report "Clinical Trials - foreign investments in Romania", made for the Romanian Association of International Drug Manufacturers (ARPIM) and the Association of Coordinating Companies for Clinical Trials in Romania (ACCSCR), was launched on September 3, 2020, in a debate attended by representatives of patients, authorities, doctors and representatives of pharmaceutical companies and companies coordinating clinical trials.
The continuous decrease in the number of clinical trials conducted in Romania was the main reason why the two associations requested IQVIA Romania a study that would provide a broader perspective on this field for all parties involved.
Although it is considered a country with potential for clinical trials, Romania's performance in attracting them is downward, with the number of studies drastically declining since 2008. Romania (98 clinical trials) lags behind smaller countries such as Bulgaria (108) and Hungary (207), as the number of clinical trials conducted in 2019 shows.
The market for clinical trials in Romania, of only 72 million EUR, could have the potential to reach EUR 802 million and even EUR 1.4 billion compared to the best performing EU countries.
See more here.
Read here the report.
